TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35017306
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for acute ischemic stroke (AIS) in patients with active cancer in a palliative treatment setting
Study: 35017306
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for acute ischemic stroke (AIS) in patients without active cancer
Study: 32310691
Drug: Momiai (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momiai (500 mg capsules)
Study: 32310691
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg capsules)
Study: 35184324
Drug: Medication consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication consultation (additional consultation with a physician)
Study: 35184324
Drug: Medication consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication consultation
Study: 34795574
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based therapy combined with conventional functional training (1 hour of functional training + 1 hour of virtual reality therapy using Armeo Spring equipment)
Study: 35612617
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (MG) - Oral dose of UC-II (1 capsule/day)
Study: 33530312
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral treatment with 3 g Clostridium butyricum
Study: 33530312
Drug: No probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No probiotic treatment
Study: 36525985
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching capsules)
Study: 34413142
Drug: Hyoscine N‐butylbromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine N‐butylbromide (20 mg intravenous injection)
Study: 34413142
Drug: Loperamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4 mg per os)
Study: 36322475
Drug: Dissolved tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolved tablet (BIC/TAF/FTC 50/200/25 mg)
Study: 36322475
Drug: Crushed tablet
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablet (BIC/TAF/FTC 50/200/25 mg)
Study: 36322475
Drug: Solid tablet
Normalized name: Corydalis solida whole extract
DrugBank: Lactobionic acid (DB16621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid tablet (BIC/TAF/FTC 50/200/25 mg)
Study: 35709600
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg daily)
Study: 33496795
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg daily)
Study: 33496795
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg daily) among Black patients
Study: 33496795
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg daily) among Black patients
Study: 33496795
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg daily) among non-Black patients
Study: 33496795
Drug: Bicalutamide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide (50 mg daily) among non-Black patients
Study: 32112428
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% cream (treatment group)
Study: 34599979
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg every 4 weeks for the first 3 doses, then every 8 weeks thereafter
Study: 33964405
Drug: Intradiscal ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal ozone infiltration (plus foraminal infiltration of ozone, steroids, and anesthetic)
Study: 33964405
Drug: Intradiscal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal oxygen infiltration (plus foraminal infiltration of oxygen, steroids, and anesthetic)
Study: 34058081
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg dipyrone
Study: 34058081
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tilidine/naloxone
Study: 34058081
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tilidine/naloxone
Study: 32050899
Drug: G-MEDSS intervention
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G-MEDSS intervention (Computerised Clinical Decision Support System)
Study: 32050899
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care HMR service (without G-MEDSS)
Study: 35588245
Drug: Viloxazine extended-release
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine extended-release (600 mg/d)
Study: 32768465
Drug: Enalapril (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (initial dose 0.10 mg/kg/d, median maximal dose 0.38 mg/kg/d)
Study: 35019882
Drug: Yoga exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga exercise program (one hour twice weekly for 12 weeks)
Study: 35881199
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (SH) eyedrops, applied 4 times daily for 2 months
Study: 35881199
Drug: Semi‐fluorinated alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi‐fluorinated alkane (SFA) eyedrops, applied 4 times daily for 2 months
Study: 36564573
Drug: Subcision combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcision combined with cross-linked HA filler injection
Study: 33539400
Drug: Self-Administered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Administered therapy (SAT)
Study: 33668674
Drug: Cheddar cheese
Normalized name: Cheddar cheese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cheddar cheese (20 g protein)
Study: 35369650
Drug: TMX-049 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMX-049 200 mg
Study: 35369650
Drug: TMX-049 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMX-049 40 mg
Study: 35369650
Drug: TMX-049 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMX-049 200 mg and 40 mg
Study: 34807241
Drug: Ciclesonide MDI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide MDI, 160 μg per actuation, 2 actuations twice a day (total daily dose, 640 μg) for 30 days
Study: 32897519
Drug: Bacillus clausii
Normalized name: BACILLUS CLAUSII
DrugBank: Bacillus clausii (DB16537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus clausii (Enterogermina®) capsules, 2 × 10^9 spores, three times daily for 2 weeks
Study: 32897519
Drug: Placebo, three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, three times daily for 2 weeks
Study: 616410548
Drug: ipragliflozin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipragliflozin (50 mg/day)
Study: 35389028
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid group (TA 250 mg twice daily)
Study: 32646428
Drug: Trehalose (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trehalose (3.3 g/day)
Study: 32646428
Drug: Sucrose (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (3.3 g/day)
Study: 35320642
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose of liposomal amphotericin B (10 mg per kilogram of body weight) on day 1 plus 14 days of flucytosine (100 mg per kilogram per day) and fluconazole (1200 mg per day)
Study: 35320642
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate (1 mg per kilogram per day) plus flucytosine (100 mg per kilogram per day) for 7 days, followed by fluconazole (1200 mg per day) for 7 days (control)
Study: 35320642
Drug: Single high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high dose of liposomal amphotericin B
Study: 34160597
Drug: Absorbable antibiotic
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absorbable antibiotic eluting envelope
Study: 32307155
Drug: Oral electrolyte
Normalized name: Hydralyte Oral Electrolyte Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral electrolyte solution (OES) administered in milk replacer (MR) and water (3 L at 1300 and 2200 h) for 4 d
Study: 32307155
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CON) receiving a small dose of whey (n = 12)
Study: 33550525
Drug: Device-aided therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Device-aided therapies (CSAI, LCIG, DBS)
Study: 32157765
Drug: Cream A
Normalized name: KIT, CREAM AND GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream A (without tranexamic acid)
Study: 32157765
Drug: Cream B
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream B (with tranexamic acid)
Study: 32157765
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (Group C)
Study: 32938411
Drug: Drug Sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Sensitive TB (DS-TB) treatment
Study: 32938411
Drug: Multi Drug
Normalized name: At Home Multi Drug Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi Drug Resistant Tuberculosis (MDR TB) treatment
Study: 32938411
Drug: General TB
Normalized name: TB-402
DrugBank: TB-402 (DB06050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: General TB treatment
Study: 32053141
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous adipose tissue-derived stromal vascular fraction (ADSVF) into 1 or 2 vocal folds.
Study: 32899067
Drug: Direct-acting oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting oral anticoagulants
Study: 33903287
Drug: Traditional anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional anticoagulants
Study: 33675348
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg resveratrol
Study: 33675348
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g resveratrol
Study: 32934137
Drug: Pegloticase in
Normalized name: pegloticase Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase in combination with Methotrexate (MTX)
Study: 32565122
Drug: 1% THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% THC dose of cannabis
Study: 32565122
Drug: 4% THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% THC dose of cannabis
Study: 32565122
Drug: 7% THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% THC dose of cannabis
Study: 32565122
Drug: THC plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC plasma levels between 16 ng/mL and 31 ng/mL
Study: 36092192
Drug: Intralesional MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional MMR (0.3 ml)
Study: 36092192
Drug: Subcutaneous MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous MMR (0.5 ml)
Study: 33039134
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine
Study: 33909172
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose glucocorticoids (GC) for induction and maintenance of remission
Study: 33909172
Drug: Mepolizumab (interleukin-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (interleukin-5 inhibitor)
Study: 33909172
Drug: Alternative immunosuppressive
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative immunosuppressive agents (e.g. mycophenolate mofetil, abatacept)
Study: 33909172
Drug: Prolonged course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged course of maintenance treatment
Study: 32192596
Drug: Gonadotropin, clomiphene,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin, clomiphene, or letrozole with IUI for four or fewer treatment cycles
Study: 33858493
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus investigational treatment (IT) with cisternal lavage using urokinase, nimodipine, and Ringer’s solution
Study: 32302056
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of macitentan (film‐coated adult formulation)
Study: 32302056
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dose of macitentan (two 5 mg dispersible tablets pediatric formulation)
Study: 33982418
Drug: Finely milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finely milled 30 mg ER tablets (EDR 6.9)
Study: 33982418
Drug: Coarsely milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarsely milled 30 mg ER tablets
Study: 33982418
Drug: Finely milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finely milled 80 mg ER tablets (EDR 4.9)
Study: 33982418
Drug: Finely milled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finely milled IR tablets
Study: 33755051
Drug: Faecal immunochemical
Normalized name: Enterococcus faecalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal immunochemical test (FIT) at cut-off values of 2 μg/g
Study: 33755051
Drug: Faecal immunochemical
Normalized name: Enterococcus faecalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal immunochemical test (FIT) at cut-off values of 10 μg/g
Study: 33755051
Drug: Faecal immunochemical
Normalized name: Enterococcus faecalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faecal immunochemical test (FIT) at cut-off values of 150 μg/g
Study: 32207414
Drug: Cervical manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical manual therapy alone (Control)
Study: 32207414
Drug: Cervical along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical along with thoracic manual therapy (Experimental)
Study: 36341464
Drug: Protein/peptide vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein/peptide vaccines
Study: 32214298
Drug: Oral ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ketamine 10 mg/kg
Study: 38869647
Drug: Oxaliplatin-based chemotherapy
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin-based chemotherapy
Study: 35179551
Drug: Ivermectin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (0.4 mg/kg body weight daily for 5 days) + standard of care
Study: 32117545
Drug: Standard Ponseti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Ponseti casting technique (once-weekly)
Study: 32117545
Drug: Accelerated Ponseti
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Ponseti casting technique (twice-weekly)
Study: 32063564
Drug: L‐Carnosine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐Carnosine 400 mg twice daily
Study: 32063564
Drug: L‐Carnosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐Carnosine
Study: 33566465
Drug: Enoxaparin prophylaxis
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin prophylaxis started less than 24 hours after insertion of central venous catheter, adjusted to anti-Xa level of 0.2-0.5 international units/mL
Study: 36108676
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B complex supplementation (thiamine 10 mg, riboflavin 4 mg, nicotinamide 40 mg, dexpanthenol 6 mg)
Study: 36125471
Drug: Tocilizumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (8 mg/kg, n=51)
Study: 32178964
Drug: Atezolizumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (840 mg) plus nab-paclitaxel (100 mg/m2)
Study: 32178964
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nab-paclitaxel (100 mg/m2)
Study: 32822325
Drug: Conventional yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional yoghurt (300 grams daily for 8 weeks)
Study: 32822325
Drug: Organic yoghurt
Normalized name: Organix Complete
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organic yoghurt (300 grams daily for 8 weeks)
Study: 34102253
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus fulvestrant (fulvestrant 500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1; ribociclib 600 mg/day, 3 weeks on, 1 week off)
Study: 34102253
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus fulvestrant (fulvestrant 500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1)
Study: 32182916
Drug: PSA_MSA algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA_MSA algorithm (combination of pixel-swapping algorithm and modified simulated annealing algorithm)
Study: 36401728
Drug: Melatonin plus
Normalized name: Nature's Truth Melatonin Plus L-Theanine 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin plus standard treatment
Study: 36078602
Drug: Acupressure wristband
Normalized name: ACUPRESSURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure wristband at P6 point applied three times daily
Study: 36078602
Drug: Regular doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular doses of intravenous antiemetics
Study: 36795891
Drug: Control medication
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control medication
Study: 34396485
Drug: Mini implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini implants in conjunction with class II elastics
Study: 34396485
Drug: Class II
Normalized name: HLA class II antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class II elastics therapy (control group)
Study: 34266402
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality treatment (Photon IMRT 50 Gy in 25 fractions + boost using 8 × 3 Gy carbon ions)
Study: 34246347
Drug: Ipatasertib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib (400 mg once daily) plus abiraterone (1000 mg once daily) and prednisolone (5 mg twice a day)
Study: 34246347
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus abiraterone (1000 mg once daily) and prednisolone (5 mg twice a day)
Study: 34047723
Drug: Ketorolac group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac group (received standard-of-care protocol, intravenous ketorolac at completion of procedure, and oral ketorolac on discharge)
Study: 34047723
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received standard-of-care pain protocol, including oxycodone-acetaminophen 5 to 325 mg on discharge)
Study: 39210472
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg daily for 3 months
Study: 32660564
Drug: sc-LCPUFA (1.19
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc-LCPUFA (1.19 g/day)
Study: 36203486
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg Rimazolam
Study: 36203486
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg Rimazolam
Study: 33545574
Drug: Compound Da-Cheng-Qi
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Da-Cheng-Qi Decoction (CDCQD), 100 ml twice a day for 7 days
Study: 33545574
Drug: Compound Da-Cheng-Qi
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Da-Cheng-Qi Decoction (CDCQD)
Study: 34000227
Drug: Islatravir 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 0.25 mg + doravirine (100 mg) + lamivudine (300 mg)
Study: 34000227
Drug: Islatravir 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 0.75 mg + doravirine (100 mg) + lamivudine (300 mg)
Study: 34000227
Drug: Islatravir 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 2.25 mg + doravirine (100 mg) + lamivudine (300 mg)
Study: 34000227
Drug: Doravirine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine (100 mg) + lamivudine (300 mg) + TDF (300 mg)
Study: 34000227
Drug: Islatravir 2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Islatravir 2.25 mg group
Study: 36375643
Drug: Liraglutide therapy
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide therapy
Study: 33929379
Drug: Induction infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction infliximab therapy
Study: 35836627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of injection terlipressin 0.02 µg/kg/min infusion and injection norepinephrine 0.01 µg/kg/min infusion
Study: 35836627
Drug: Norepinephrine 0.01
Normalized name: norepinephrine 0.016 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 0.01 µg/kg/min infusion alone
Study: 35836627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of injection terlipressin and norepinephrine
Study: 36706355
Drug: Ipilimumab monotherapy
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab monotherapy
Study: 35996199
Drug: TQG202 prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQG202 prophylaxis (30 ± 5 IU/kg initial dose for 24 weeks)
Study: 33920292
Drug: Caffeine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2 × 2.5 mg/kg/24 h)
Study: 32652314
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (IAIs) 2 mg every 4 weeks
Study: 32652314
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (IAIs) 2 mg every 8 weeks after 3 initial monthly doses
Study: 33077012
Drug: Lurasidone (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (20-80 mg/day)